Curis (NASDAQ:CRIS – Get Rating)‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a report released on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Curis’ FY2022 earnings at ($0.69) EPS and FY2023 earnings at ($0.80) EPS.
Curis Trading Up 1.1 %
Shares of CRIS opened at $0.79 on Wednesday. The firm’s 50-day moving average is $1.02 and its two-hundred day moving average is $1.26. Curis has a twelve month low of $0.70 and a twelve month high of $8.50. The firm has a market capitalization of $72.50 million, a P/E ratio of -1.28 and a beta of 2.64.
Curis (NASDAQ:CRIS – Get Rating) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.17) earnings per share for the quarter, hitting the consensus estimate of ($0.17). Curis had a negative net margin of 533.89% and a negative return on equity of 68.41%. During the same quarter last year, the company earned ($0.12) EPS. Analysts predict that Curis will post -0.69 EPS for the current year.
Institutional Trading of Curis
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.
- Get a free copy of the StockNews.com research report on Curis (CRIS)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.